Epidemiology of Invasive Pneumococcal Disease in Older People in Spain (2007–2009): Implications for Future Vaccination Strategies

Abstract

BackgroundRecently, the 13-valent pneumococcal conjugate vaccine (PCV13) has been recommended for adults. We analyzed the epidemiology of invasive pneumococcal disease (IPD) in older adults in Spain before PCV13 introduction.Methodology/Principal FindingsIPD episodes, defined as clinical findings together with an invasive pneumococcal isolate, were prospectively collected from patients aged over 65 years in three hospitals in Spain from 2007 to 2009. A total of 335 IPD episodes were collected. Pneumonia was the main clinical syndrome, while chronic obstructive pulmonary disease, diabetes mellitus and cancer were the main underlying diseases. Pneumococcal isolates were serotyped and the molecular typing was performed by PFGE/MLST. PCV13 serotypes accounted for 59.3% of isolates, the most prevalent being serotypes 19A (15.1%), 3 (9.6%), 7F (7.5%), 14 (6.9%) and 1 (5.4%). The most frequent non-PCV13 serotypes were serotypes 16F (4.5%), 22F (3.6%), 24F (3.3%) and 6C (2.1%). The most common genotypes were CC230 (8.5%, serotypes 19A and 24F), CC156 (8.2%, serotypes 9V and 14), ST191 (7.9%, serotype 7F), CC260 (6.6%, serotype 3), ST306 (5.2%, serotype 1), CC30 (4.6%, serotype 16F) and ST433 (3.6%, serotype 22F). Comparing the 335 IPD isolates to 174 invasive pneumococci collected at the same hospitals in 1999–2000, PCV7 serotypes decreased (45.4% vs 18.4%,p<0.001), non-PCV7 serotypes included in PCV13 increased (26.4% vs 41.0%,p = 0.001) and two non-PCV13 serotypes increased (serotype 6C 0% vs 2.1%, p = 0.05; serotype 24F 0.6% vs 3.3%, p = 0.04,).ConclusionIn our older adult population two serotypes (19A and 3) included in PCV13 accounted for about a quarter of IPD episodes in people ≥65 years. Non-PCV13 emerging serotypes should be carefully monitored in future surveillance studies.

Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care

“…There is little evidence to show the effectiveness of other vaccinations (pertussis, heamophilus), these should therefore not be included in standard treatment 2,4,[75][76][77][78] . Treatment of comorbidities: In addition to the treatment of COPD, it is necessary to consider reasonable and effective therapeutic interventions for all comorbidities 2 .…”

A Pneumococcal Protein Array as a Platform to Discover Serodiagnostic Antigens Against Infection

“…Some of the isolates belonged to the most prevalent and virulent serotypes circulating in Spain in the last years (1, 3, 7F, 14, and 19A) (50). The identifications included numerous cytoplasmic proteins, which may be because of unavoidable lysis (21,29).…”

Molecular characterization of non-vaccine Streptococcus pneumoniae serotypes 11A, 15 B/C and 23A recovered from invasive isolates in Colombia

“…Surveillance programs results suggest that the prevalence of pneumococci of various serotypes not included in the conjugated vaccines is rapidly increasing worldwide (e.g., 11, 12, 15, 22F, 23A, 23B, 33F, 24, 34, and 35B) (13,14).…”